Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AC137 amylin mimic data

AMLN presented data gathered in a Phase II pharmacokinetic study of the amylin mimic AC137 showing an unexpected dampening of glucose blood levels in diabetics after meals. AMLN found that

Read the full 303 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE